ApexOnco Front Page Recent articles 14 March 2025 Sutro calls time on folate At long last luvelta-T is shelved, and Sutro seeks a new focus. 13 March 2025 Ono takes on Takeda in polycythemia vera The Japanese group licenses sapablursen from Ionis for $280m. 11 October 2024 Regeneron’s fianlimab lung test approaches The company reckons it can outdo Bristol’s relatlimab in first-line NSCLC. 9 October 2024 Triple meeting 2024 – plenary focus Aktis scores a plenary, as do Tyra’s FGFR3 inhibitor and Arcus’s HIF-2α contender. 9 October 2024 Triple meeting 2024 – can Revolution succeed where others stumbled? The group will present the first clinical data on its KRAS G12D-selective project RMC-9805. 8 October 2024 Vincerx stalls again The group reports responses with its CD123-targeting ADC, but cash is running short. 7 October 2024 Ipsen casts doubt on Pfizer’s prostate plan Mevrometostat is the only EZH2 inhibitor in phase 3 for prostate cancer. 4 October 2024 J&J ramps up its bladder cancer battle The first approval for TAR-200 is on the horizon, setting up a challenge to Keytruda. Load More Recent Quick take AACR 2024 – indolent lymphoma presents fresh CD47 promise 11 April 2024 Arvinas degraders get another vote of confidence 11 April 2024 AACR 2024 – US accelerated approvals come under more fire 9 April 2024 Tracon’s subcutaneous hopes evaporate 5 April 2024 Erasca heads for phase 3 at last 4 April 2024 BioNTech and DualityBio branch out 4 April 2024 Carisma switches cells 3 April 2024 Ipsen buys into ROR1 after Boehringer’s exit 2 April 2024 Bristol bids to outdo Amgen in KRAS 2 April 2024 The first-quarter curtain falls on Pieris and Gamida 28 March 2024 Load More Most Popular